BNR
Burning Rock Biotech Limited
Price Chart
Latest Quote
$9.61
+0.01 (+0.05%)
Current Price
| Previous Close | $9.60 |
| Open | $9.30 |
| Day High | $9.82 |
| Day Low | $9.05 |
| Volume | 15,268 |
Stock Information
Note: Financial values converted from CNY to USD
| Shares Outstanding | 8.81M |
| Total Debt | $7.51M |
| Cash Equivalents | $65.81M |
| Revenue | $75.91M |
| Net Income | $-8.75M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $105.15M |
| EPS (TTM) | $-0.85 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-290.26M |
| Sales | $75.91M |
| Income | $-8.75M |
| Book/sh | $7.25 |
| Cash/sh | $50.60 |
| Employees | 667 |
Financial Ratios
| Quick Ratio | 2.71 |
| Current Ratio | 3.05 |
| Debt/Eq | 9.85 |
Returns & Margins
| ROA | -4.45% |
| ROE | -10.90% |
| Gross Margin | 74.55% |
| Operating Margin | -17.46% |
| Profit Margin | -11.53% |
Ownership
| Insider Ownership | 4.01% |
| Institutional Ownership | 46.67% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -17.19 |
| P/S | 0.20 |
| P/B | 1.37 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $9.39 |
| SMA50 | $11.26 |
| SMA200 | $17.71 |
| RSI | 62.18 |
| ATR | 1.0771 |
| Shares Float | 3.32M |
| Short Float | 0.49% |
| Short Ratio | 1.29 |
| Volatility | 1.33 |
| Rel Volume | 0.16 |
Performance History
| Week | -11.77% |
| Month | +22.63% |
| Quarter | -55.69% |
| 6 Months | -65.04% |
| YTD | -49.34% |
| Year | +116.74% |
| 3 Years | -54.78% |
| 5 Years | -96.36% |
| 10 Years | -95.95% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $9.97 | 4,100 |
| 2026-07-16 | $9.60 | 15,500 |
| 2026-07-15 | $9.30 | 15,100 |
| 2026-07-14 | $9.94 | 7,400 |
| 2026-07-13 | $10.66 | 23,600 |
| 2026-07-10 | $11.30 | 25,700 |
| 2026-07-09 | $11.70 | 25,300 |
| 2026-07-08 | $11.75 | 39,900 |
| 2026-07-07 | $10.74 | 89,800 |
| 2026-07-06 | $10.33 | 9,300 |
| 2026-07-02 | $9.82 | 29,400 |
| 2026-07-01 | $8.96 | 8,300 |
| 2026-06-30 | $8.37 | 15,000 |
| 2026-06-29 | $8.08 | 12,900 |
| 2026-06-26 | $8.27 | 10,000 |
| 2026-06-25 | $7.95 | 27,900 |
| 2026-06-24 | $8.52 | 62,300 |
| 2026-06-23 | $7.56 | 11,000 |
| 2026-06-22 | $7.73 | 39,000 |
| 2026-06-18 | $7.25 | 26,100 |
About Burning Rock Biotech Limited
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $20,216,585 | $22,697,241 | $25,772,321 | $27,102,449 |
| Cost Of Revenue | $20,216,585 | $22,697,241 | $25,772,321 | $27,102,449 |
| Total Revenue | $79,823,658 | $76,310,676 | $79,508,102 | $83,325,396 |
| Operating Revenue | $79,823,658 | $76,310,676 | $79,508,102 | $83,325,396 |
| Expenses | ||||
| Interest Expense | $4,438 | $0 | $0 | - |
| Total Expenses | $87,937,424 | $124,011,246 | $178,527,410 | $228,366,749 |
| Other Income Expense | $-1,030,846 | $-4,515,275 | $9,468 | $251,646 |
| Other Non Operating Income Expenses | $-38,021 | $696,205 | $71,603 | $22,487 |
| Net Non Operating Interest Income Expense | $1,186,922 | $1,806,643 | $2,656,410 | $1,399,216 |
| Interest Expense Non Operating | $4,438 | $0 | $0 | - |
| Operating Expense | $67,720,839 | $101,314,005 | $152,755,089 | $201,264,300 |
| Selling And Marketing Expense | $24,435,980 | $28,242,326 | $36,646,350 | $54,781,272 |
| General And Administrative Expense | $18,653,747 | $38,706,710 | $64,771,212 | $84,071,901 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,187,884 | $-51,279,830 | $-96,706,711 | $-143,684,152 |
| Net Interest Income | $1,186,922 | $1,806,643 | $2,656,410 | $1,399,216 |
| Interest Income | $1,191,360 | $1,806,643 | $2,656,410 | $1,399,216 |
| Normalized Income | $-7,443,265 | $-47,371,219 | $-96,660,110 | $-143,856,021 |
| Net Income From Continuing And Discontinued Operation | $-8,187,884 | $-51,279,830 | $-96,706,711 | $-143,684,152 |
| Total Operating Income As Reported | $-8,113,766 | $-52,897,257 | $-99,019,309 | $-145,041,353 |
| Net Income Common Stockholders | $-8,187,884 | $-51,279,830 | $-96,706,711 | $-143,684,152 |
| Net Income | $-8,187,884 | $-51,279,830 | $-96,706,711 | $-143,684,152 |
| Net Income Including Noncontrolling Interests | $-8,187,884 | $-51,279,830 | $-96,706,711 | $-143,684,152 |
| Net Income Continuous Operations | $-8,187,884 | $-51,279,830 | $-96,706,711 | $-143,684,152 |
| Pretax Income | $-7,957,689 | $-50,409,203 | $-96,353,431 | $-143,390,491 |
| Special Income Charges | $0 | $-5,196,686 | $0 | $0 |
| Interest Income Non Operating | $1,191,360 | $1,806,643 | $2,656,410 | $1,399,216 |
| Operating Income | $-8,113,766 | $-47,700,571 | $-99,019,309 | $-145,041,353 |
| Gross Profit | $59,607,073 | $53,613,434 | $53,735,781 | $56,222,947 |
| Per Share | ||||
| Diluted EPS | $-0.75 | $-4.99 | $-9.44 | $-13.83 |
| Basic EPS | $-0.75 | $-4.99 | $-9.44 | $-13.83 |
| Other | ||||
| Tax Effect Of Unusual Items | $-248,206 | $-1,302,870 | $-15,534 | $57,290 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,741,105 | $-37,475,258 | $-76,556,108 | $-126,911,757 |
| Total Unusual Items | $-992,825 | $-5,211,480 | $-62,135 | $229,159 |
| Total Unusual Items Excluding Goodwill | $-992,825 | $-5,211,480 | $-62,135 | $229,159 |
| Reconciled Depreciation | $3,219,321 | $7,722,465 | $19,735,188 | $18,358,755 |
| EBITDA (Bullshit earnings) | $-4,733,930 | $-42,686,738 | $-76,618,243 | $-126,682,598 |
| EBIT | $-7,953,251 | $-50,409,203 | $-96,353,431 | $-145,041,353 |
| Diluted Average Shares | $1,595,548 | $1,522,820 | $1,514,854 | $1,537,228 |
| Basic Average Shares | $1,595,548 | $1,522,820 | $1,514,854 | $1,537,228 |
| Diluted NI Availto Com Stockholders | $-8,187,884 | $-51,279,830 | $-96,706,711 | $-143,684,152 |
| Tax Provision | $230,195 | $870,627 | $353,281 | $293,661 |
| Impairment Of Capital Assets | $0 | $5,196,686 | $0 | $0 |
| Gain On Sale Of Security | $-992,825 | $-14,794 | $-62,135 | $229,159 |
| Research And Development | $24,631,112 | $34,364,969 | $51,337,526 | $62,411,127 |
| Selling General And Administration | $43,089,727 | $66,949,036 | $101,417,563 | $138,853,173 |
| Other Gand A | $18,653,747 | $38,706,710 | $64,771,212 | $84,071,901 |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $79,144,909 | $85,865,229 | $113,535,915 | $171,071,089 |
| Total Assets | $121,366,228 | $130,971,969 | $153,857,686 | $234,849,773 |
| Total Non Current Assets | $12,099,860 | $16,079,148 | $23,064,576 | $48,628,598 |
| Other Non Current Assets | $1,129,078 | $1,172,572 | $752,718 | $3,090,465 |
| Goodwill And Other Intangible Assets | $42,015 | $62,283 | $142,614 | $293,809 |
| Other Intangible Assets | $42,015 | $62,283 | $142,614 | $293,809 |
| Current Assets | $109,266,369 | $114,892,820 | $130,793,109 | $186,221,175 |
| Other Current Assets | $55,921 | $58,436 | $413,936 | $1,527,628 |
| Current Deferred Assets | $1,242,548 | $1,311,044 | $0 | - |
| Restricted Cash | $398,846 | $342,185 | $17,753 | $2,931,726 |
| Prepaid Assets | $1,093,868 | $2,661,292 | $4,327,243 | $3,345,958 |
| Inventory | $7,186,331 | $7,953,695 | $10,210,815 | $19,279,681 |
| Receivables | $28,515,571 | $25,659,739 | $24,826,097 | $25,183,816 |
| Other Receivables | $1,819,809 | $2,049,708 | $3,365,338 | $6,177,528 |
| Taxes Receivable | $1,593,165 | $1,095,051 | $2,518,973 | $2,724,462 |
| Accrued Interest Receivable | $10,356 | $26,185 | $174,421 | $15,238 |
| Accounts Receivable | $25,092,241 | $22,488,794 | $18,767,365 | $16,266,588 |
| Allowance For Doubtful Accounts Receivable | $-8,766,033 | $-6,785,561 | $-5,680,302 | $-6,348,695 |
| Gross Accounts Receivable | $33,858,274 | $29,274,355 | $24,447,667 | $22,615,283 |
| Cash Cash Equivalents And Short Term Investments | $70,773,284 | $76,906,430 | $90,997,265 | $133,952,367 |
| Cash And Cash Equivalents | $70,773,284 | $76,906,430 | $90,997,265 | $133,952,367 |
| Non Current Note Receivables | - | $0 | $787,040 | $755,233 |
| Loans Receivable | - | - | - | $0 |
| Debt | ||||
| Total Debt | $6,379,170 | $7,740,366 | $1,823,212 | $7,513,426 |
| Long Term Debt And Capital Lease Obligation | $3,869,813 | $4,105,925 | $545,898 | $2,004,734 |
| Long Term Debt | $251,498 | - | - | - |
| Current Debt And Capital Lease Obligation | $2,509,357 | $3,634,441 | $1,277,313 | $5,508,692 |
| Current Debt | $29,588 | - | - | - |
| Other Current Borrowings | $29,588 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $42,179,304 | $45,044,457 | $40,179,156 | $63,484,875 |
| Total Non Current Liabilities Net Minority Interest | $5,641,394 | $5,648,199 | $1,217,102 | $2,614,838 |
| Other Non Current Liabilities | $1,771,581 | $1,542,274 | $671,204 | $610,104 |
| Current Liabilities | $36,537,911 | $39,396,258 | $38,962,054 | $60,870,036 |
| Other Current Liabilities | $1,848,214 | $2,711,887 | $2,802,722 | $2,900,658 |
| Current Deferred Liabilities | $16,038,317 | $17,528,960 | $19,488,720 | $22,107,553 |
| Payables And Accrued Expenses | $16,142,023 | $15,520,971 | $15,393,299 | $24,587,618 |
| Payables | $8,451,217 | $7,131,445 | $5,722,317 | $9,168,134 |
| Total Tax Payable | $2,423,552 | $2,138,916 | $3,050,374 | $1,631,038 |
| Accounts Payable | $6,027,665 | $4,992,529 | $2,671,943 | $7,537,096 |
| Interest Payable | - | - | - | $0 |
| Non Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $79,186,924 | $85,927,512 | $113,678,529 | $171,364,898 |
| Total Equity Gross Minority Interest | $79,186,924 | $85,927,512 | $113,678,529 | $171,364,898 |
| Stockholders Equity | $79,186,924 | $85,927,512 | $113,678,529 | $171,364,898 |
| Gains Losses Not Affecting Retained Earnings | $-23,986,538 | $-23,381,612 | $-23,897,182 | $-24,516,903 |
| Other Equity Adjustments | $-23,986,538 | $-23,381,612 | $-23,897,182 | $-24,516,903 |
| Retained Earnings | $-629,574,244 | $-621,386,360 | $-570,106,531 | $-473,399,819 |
| Long Term Equity Investment | - | $0 | $49,856 | $102,079 |
| Other | ||||
| Treasury Shares Number | $447,243 | $447,243 | $447,243 | $447,243 |
| Ordinary Shares Number | $15,560,706 | $15,920,404 | $15,155,034 | $15,185,065 |
| Share Issued | $16,007,949 | $16,367,647 | $15,602,277 | $15,632,308 |
| Tangible Book Value | $79,144,909 | $85,865,229 | $113,535,915 | $171,071,089 |
| Invested Capital | $79,468,010 | $85,927,512 | $113,678,529 | $171,364,898 |
| Working Capital | $72,728,458 | $75,496,562 | $91,831,055 | $125,351,139 |
| Capital Lease Obligations | $6,098,084 | $7,740,366 | $1,823,212 | $7,513,426 |
| Total Capitalization | $79,438,422 | $85,927,512 | $113,678,529 | $171,364,898 |
| Treasury Stock | $8,461,129 | $9,359,272 | $9,748,650 | $8,716,473 |
| Additional Paid In Capital | $741,187,976 | $740,033,305 | $717,410,625 | $677,977,678 |
| Capital Stock | $20,860 | $21,451 | $20,268 | $20,416 |
| Common Stock | $20,860 | $21,451 | $20,268 | $20,416 |
| Long Term Capital Lease Obligation | $3,618,315 | $4,105,925 | $545,898 | $2,004,734 |
| Current Deferred Revenue | $16,038,317 | $17,528,960 | $19,488,720 | $22,107,553 |
| Current Capital Lease Obligation | $2,479,769 | $3,634,441 | $1,277,313 | $5,508,692 |
| Current Accrued Expenses | $7,690,806 | $8,389,526 | $9,670,982 | $15,419,484 |
| Net PPE | $10,928,767 | $14,844,294 | $21,332,348 | $44,387,012 |
| Accumulated Depreciation | $-72,530,514 | $-71,214,293 | $-59,782,234 | $-41,023,449 |
| Gross PPE | $83,459,282 | $86,058,586 | $81,114,581 | $85,410,461 |
| Leases | $27,668,911 | $27,698,055 | $27,722,465 | $27,720,838 |
| Construction In Progress | $93,794 | $93,794 | $81,071 | $393,372 |
| Other Properties | $12,969,747 | $15,591,538 | $9,575,561 | $14,790,887 |
| Machinery Furniture Equipment | $42,726,830 | $42,675,199 | $43,735,484 | $42,505,364 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,331,238 | $2,118,352 | $3,115,467 | $5,223,315 |
| Work In Process | $646,941 | $978,919 | $777,868 | $1,122,272 |
| Raw Materials | $4,208,152 | $4,856,424 | $6,317,479 | $12,934,093 |
| Investments And Advances | - | $0 | $49,856 | $102,079 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | $0 | $5,765,515 |
| Other Short Term Investments | - | - | - | $0 |
| Non Current Deferred Revenue | - | - | - | - |
| Duefrom Related Parties Current | - | - | - | - |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,984,392 | $-14,533,324 | $-39,228,790 | $-78,006,215 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,207,856 | $-13,649,087 | $-37,840,522 | $-67,580,148 |
| Cash Flow From Continuing Operating Activities | $-4,207,856 | $-13,649,087 | $-37,840,522 | $-67,580,148 |
| Operating Gains Losses | $-30,180 | $339,226 | $202,530 | $253,273 |
| Investing Activities | ||||
| Capital Expenditure | $-776,537 | $-884,237 | $-1,388,268 | $-10,426,067 |
| Investing Cash Flow | $-649,604 | $-652,711 | $-1,375,841 | $-1,104,076 |
| Cash Flow From Continuing Investing Activities | $-649,604 | $-652,711 | $-1,375,841 | $-1,104,076 |
| Net Other Investing Changes | - | - | - | $-739,700 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-10,652 | $-1,032,177 | $-10,627,118 |
| Financing Cash Flow | $281,086 | $-10,652 | $-7,224,203 | $-12,758,192 |
| Cash Flow From Continuing Financing Activities | $281,086 | $-10,652 | $-7,224,203 | $-12,758,192 |
| Net Common Stock Issuance | $0 | $-10,652 | $-1,032,177 | $-10,627,118 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Other Financing Charges | - | - | - | $-1,780,457 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-14,794 | $0 | $0 | $-350,618 |
| Issuance Of Debt | $295,880 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $4,438 | $0 | $0 | $129,743 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $14,498 |
| End Cash Position | $71,172,130 | $77,248,615 | $91,015,018 | $136,884,092 |
| Beginning Cash Position | $77,248,615 | $91,015,018 | $136,884,092 | $212,902,143 |
| Effect Of Exchange Rate Changes | $-1,500,111 | $546,046 | $571,492 | $5,424,366 |
| Changes In Cash | $-4,576,374 | $-14,312,449 | $-46,440,566 | $-81,442,416 |
| Proceeds From Stock Option Exercised | $0 | $0 | $-6,192,026 | $-1,780,457 |
| Common Stock Payments | $0 | $-10,652 | $-1,032,177 | $-10,627,118 |
| Net Issuance Payments Of Debt | $281,086 | $0 | $0 | $-350,618 |
| Net Long Term Debt Issuance | $281,086 | $0 | $0 | $0 |
| Long Term Debt Payments | $-14,794 | $0 | $0 | $0 |
| Long Term Debt Issuance | $295,880 | $0 | $0 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-82,550 | $-189,363 | $-27,369 |
| Purchase Of Intangibles | $0 | $-82,550 | $-189,363 | $-27,369 |
| Net PPE Purchase And Sale | $-649,604 | $-570,161 | $-1,186,478 | $-10,041,571 |
| Sale Of PPE | $126,932 | $231,526 | $12,427 | $357,127 |
| Purchase Of PPE | $-776,537 | $-801,687 | $-1,198,905 | $-10,398,698 |
| Change In Working Capital | $-8,785,857 | $-5,404,542 | $-7,716,103 | $-1,650,862 |
| Change In Other Working Capital | $-1,524,521 | $-2,087,137 | $-2,555,662 | $925,512 |
| Change In Other Current Liabilities | $-3,716,251 | $-4,085,953 | $-5,583,845 | $-5,593,757 |
| Change In Payables And Accrued Expense | $47,045 | $1,509,579 | $-7,451,883 | $7,440,491 |
| Change In Accrued Expense | $-1,014,572 | $-1,285,302 | $-2,847,400 | $4,979,954 |
| Change In Payable | $1,061,617 | $2,794,881 | $-4,604,483 | $2,460,537 |
| Change In Account Payable | $1,061,617 | $2,794,881 | $-4,604,483 | $2,460,537 |
| Change In Prepaid Assets | $953,769 | $2,852,578 | $1,827,502 | $5,017,975 |
| Change In Inventory | $369,554 | $371,033 | $8,473,556 | $-3,203,491 |
| Change In Receivables | $-4,915,452 | $-3,964,642 | $-2,425,771 | $-6,237,592 |
| Changes In Account Receivables | $-4,583,919 | $-4,826,688 | $-1,832,384 | $-3,181,448 |
| Other Non Cash Items | $3,615,208 | $3,897,626 | $5,204,971 | $5,469,931 |
| Stock Based Compensation | $2,052,815 | $23,022,709 | $38,570,753 | $48,344,405 |
| Unrealized Gain Loss On Investment Securities | $899,327 | $787,040 | $-31,807 | $-15,534 |
| Provisionand Write Offof Assets | $3,009,394 | $2,032,991 | $2,900,658 | $5,344,034 |
| Asset Impairment Charge | $0 | $5,233,227 | $0 | $0 |
| Depreciation Amortization Depletion | $3,219,321 | $7,722,465 | $19,735,188 | $18,358,755 |
| Depreciation And Amortization | $3,219,321 | $7,722,465 | $19,735,188 | $18,358,755 |
| Earnings Losses From Equity Investments | $0 | $13,758 | $53,406 | $43,494 |
| Gain Loss On Sale Of PPE | $-30,180 | $325,468 | $149,123 | $209,779 |
| Net Income From Continuing Operations | $-8,187,884 | $-51,279,830 | $-96,706,711 | $-143,684,152 |
| Net Short Term Debt Issuance | - | $0 | $0 | $-350,618 |
| Short Term Debt Payments | - | $0 | $0 | $-350,618 |
| Net Investment Purchase And Sale | - | $0 | $0 | $9,704,564 |
| Sale Of Investment | - | $0 | $0 | $9,704,564 |
| Amortization Cash Flow | - | $120,275 | $288,187 | $495,451 |
| Amortization Of Intangibles | - | $120,275 | $288,187 | $495,451 |
| Depreciation | - | $7,602,190 | $19,447,001 | $17,863,304 |
| Purchase Of Investment | - | - | $0 | $0 |
| Preferred Stock Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-07-15